Programmed cell death protein 1 and multi-kinase signaling axes (PD-1/MKI)

The combined PD-1 checkpoint and multi-kinase signaling axes represent a multi-target therapeutic strategy that integrates immune system reactivation with the inhibition of tumor growth and angiogenesis. Programmed cell death protein 1 (PD-1) is an inhibitory receptor expressed on T cells that limits their activity to prevent autoimmunity, but is often exploited by tumors to evade immune surveillance (UniProt: Q15116). Multi-kinase signaling axes involve various receptor tyrosine kinases, such as Vascular Endothelial Growth Factor Receptors (VEGFRs), Fibroblast Growth Factor Receptors (FGFRs), and Platelet-Derived Growth Factor Receptors (PDGFRs), which promote tumor vascularization and proliferation (PMID: 32690440). Combining PD-1 inhibitors with multi-kinase inhibitors (MKIs) creates a synergistic effect where the MKI remodels the immunosuppressive tumor microenvironment—by reducing myeloid-derived suppressor cells and increasing T-cell infiltration—thereby enhancing the efficacy of the checkpoint blockade (PMID: 34432537). This dual approach is clinically validated and FDA-approved for several aggressive malignancies, including advanced renal cell carcinoma and endometrial cancer (FDA.gov). However, the combination is associated with a distinct safety profile that includes both immune-related adverse events and MKI-specific toxicities like hypertension and hand-foot syndrome.

Other names

PD-1 and VEGFR/FGFR/PDGFR inhibitionImmune checkpoint and multi-tyrosine kinase inhibitor combinationPD-1/MKI axisPD-1 plus multi-kinase signaling axis

Simultaneous blockade of the PD-1 immune checkpoint to restore T-cell mediated anti-tumor immunity and inhibition of multiple receptor tyrosine kinases (such as VEGFR, FGFR, and PDGFR) to disrupt angiogenesis and oncogenic signaling pathways.